India, Dec. 22 -- Cipla Limited on Monday announced the launch of an orally inhaled insulin powder for diabetes management in India, offering patients a convenient, needle-free alternative to traditional injectable insulin therapy.
The Mumbai-based drug maker said it had received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) late last year for the exclusive distribution and marketing of Afrezza, a rapid-acting inhalable insulin.
Cipla said the introduction of the product is expected to benefit a large section of India's diabetes population, with nearly 10 crore adults currently living with diabetes mellitus, by improving ease of use and treatment adherence.
Published by HT Digital Content Services with ...